Precipio Swings to Profit on Strong Revenue Growth, ERC Boost

TL;DR

**PRPO's surprise quarterly profit is a positive sign, but don't get too excited; the 'going concern' warning still looms large, making it a high-risk bet.**

AI Summary

Precipio, Inc. (PRPO) reported a significant turnaround in its financial performance for the three months ended June 30, 2025, achieving a net income of $74,000, a substantial improvement from the net loss of $1.22 million in the same period of 2024. This positive shift was primarily driven by a 25.3% increase in total revenue, reaching $5.65 million from $4.44 million year-over-year, with service revenue growing by 28.0% to $5.005 million. The company also recognized $789,000 from an Employee Retention Credit and a $143,000 gain on settlement of liability, contributing to the net income. Despite the quarterly profit, Precipio still recorded a net loss of $810,000 for the six months ended June 30, 2025, though this is a considerable improvement from the $3.299 million loss in the prior year. The company's accumulated deficit stands at $103.3 million as of June 30, 2025, and it faces a working capital deficit of $0.3 million, raising substantial doubt about its ability to continue as a going concern for the next twelve months. Precipio is actively utilizing its AGP 2023 Sales Agreement, with approximately $3.7 million available for future common stock sales to address its capital needs.

Why It Matters

Precipio's unexpected quarterly net income of $74,000, driven by robust service revenue growth and a significant Employee Retention Credit, offers a glimmer of hope for investors in this struggling cancer diagnostics company. While the long-term 'going concern' risk remains due to a $103.3 million accumulated deficit and a $0.3 million working capital deficit, the revenue increase suggests potential operational improvements and market acceptance of its diagnostic products. For employees, continued revenue growth could stabilize job security, while customers might benefit from accelerated product development if the company can secure additional financing. In a competitive diagnostics market, sustained revenue growth and a path to consistent profitability are crucial for Precipio to differentiate itself and alleviate investor concerns.

Risk Assessment

Risk Level: high — Precipio explicitly states 'substantial doubt about the Company's ability to continue as a going concern for the next twelve months' due to an accumulated deficit of $103.3 million and a working capital deficit of $0.3 million as of June 30, 2025. While the company generated $309,000 in net cash from operating activities for the six months ended June 30, 2025, it still incurred an operating loss of $1.7 million for the same period, indicating ongoing operational challenges.

Analyst Insight

Investors should approach PRPO with extreme caution, recognizing the explicit 'going concern' risk. While the recent quarterly profit is a positive data point, it's heavily influenced by one-time items like the Employee Retention Credit. Monitor future filings closely for sustained organic revenue growth and a clear path to consistent profitability, as well as successful utilization of the remaining $3.7 million from the AGP 2023 Sales Agreement to address liquidity concerns before considering any investment.

Financial Highlights

debt To Equity

0.53

revenue

$5.65 million

operating Margin

42.9%

total Assets

$18.816 million

total Debt

$0.79 million

net Income

$74,000

eps

N/A

gross Margin

42.9%

cash Position

$1.13 million

revenue Growth

+25.3%

Revenue Breakdown

Key Numbers

• $74,000 — Net Income (for the three months ended June 30, 2025, a significant improvement from a $1.22 million net loss in Q2 2024)
• $5.65 million — Net Sales (for the three months ended June 30, 2025, up 25.3% from $4.44 million in Q2 2024)
• $5.005 million — Service Revenue (for the three months ended June 30, 2025, up 28.0% from $3.909 million in Q2 2024)
• $789,000 — Employee Retention Credit (recognized as other income for the three and six months ended June 30, 2025)
• $103.3 million — Accumulated Deficit (as of June 30, 2025, indicating significant historical losses)
• $0.3 million — Working Capital Deficit (as of June 30, 2025, highlighting short-term liquidity challenges)
• $3.7 million — Available for Future Sales (under the AGP 2023 Sales Agreement as of the filing date)
• $810,000 — Net Loss (for the six months ended June 30, 2025, an improvement from a $3.299 million loss in the prior year)
• $309,000 — Net Cash Provided by Operating Activities (for the six months ended June 30, 2025, a positive shift from cash used in prior periods)

Key Players & Entities

• Precipio, Inc. (company) — registrant
• A.G.P./Alliance Global Partners (company) — sales agent for common stock offerings
• SEC (regulator) — U.S. Securities and Exchange Commission
• Nasdaq Capital Market (market) — exchange where common stock is registered
• ThermoFisher (company) — global healthcare distributor
• McKesson (company) — global healthcare distributor
• Medline (company) — global healthcare distributor
• Cardinal Health (company) — global healthcare distributor
• FASB (regulator) — Financial Accounting Standards Board

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $103.3 million and a working capital deficit of $0.3 million as of June 30, 2025. This raises substantial doubt about its ability to continue as a going concern for the next twelve months.
• Reliance on Equity Financing [medium — financial]: Precipio has approximately $3.7 million available for future common stock sales under its AGP 2023 Sales Agreement. This indicates a continued reliance on external capital to fund operations and address liquidity needs.
• Intangible Assets Valuation [medium — operational]: The company holds $11.394 million in intangible assets as of June 30, 2025. Fluctuations in the value or impairment of these assets could significantly impact the balance sheet.
• Employee Retention Credit Recognition [low — regulatory]: The recognition of $789,000 from the Employee Retention Credit as other income in the current quarter significantly boosted net income. Future periods will not have this one-time benefit.

Industry Context

The diagnostic testing and healthcare services industry is highly competitive and subject to stringent regulatory oversight. Companies in this sector often face pressure on pricing and reimbursement, alongside the need for continuous innovation and efficient operations. Precipio operates within this dynamic environment, focusing on specialized diagnostic solutions.

Regulatory Implications

The company's financial reporting is subject to SEC regulations. The 'going concern' disclosure highlights a significant risk that could trigger closer scrutiny from regulators and investors if not adequately addressed. Compliance with healthcare regulations remains paramount.

What Investors Should Do

1. Monitor cash burn and working capital trends closely.
2. Evaluate the sustainability of revenue growth beyond one-time benefits.
3. Assess the company's strategy for addressing the going concern issue.
4. Analyze the utilization and impact of the AGP 2023 Sales Agreement.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported net income of $74,000 on revenue of $5.65 million, a significant improvement from Q2 2024.
• 2025-06-30: Balance Sheet Date — Accumulated deficit of $103.3 million and working capital deficit of $0.3 million highlight ongoing financial challenges.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability, standing at $103.3 million as of June 30, 2025.)

Working Capital Deficit

Occurs when a company's current liabilities exceed its current assets, indicating potential short-term liquidity issues. (Precipio has a working capital deficit of $0.3 million as of June 30, 2025, raising concerns about its ability to meet short-term obligations.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (The company's financial condition raises substantial doubt about its ability to continue as a going concern.)

Employee Retention Credit (ERC)

A refundable tax credit for businesses that continued to pay employees during the COVID-19 pandemic. (Precipio recognized $789,000 from this credit, which significantly boosted its quarterly net income.)

AGP 2023 Sales Agreement

An agreement allowing the company to sell shares of its common stock to an investor (Ascendiant Capital Markets, LLC) over time. (Provides a potential source of capital, with $3.7 million available for future sales.)

Year-Over-Year Comparison

Precipio has demonstrated a significant improvement in its top-line performance, with net sales increasing by 25.3% to $5.65 million in Q2 2025 compared to the prior year. This revenue growth has translated into a positive net income of $74,000 for the quarter, a stark contrast to the $1.22 million net loss in Q2 2024. However, the company continues to grapple with a substantial accumulated deficit of $103.3 million and a working capital deficit of $0.3 million, raising ongoing concerns about its long-term viability and ability to operate as a going concern.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share PRPO The Nasdaq

Filing Documents

• prpo-20250630x10q.htm (10-Q) — 1810KB
• prpo-20250630xex31d1.htm (EX-31.1) — 13KB
• prpo-20250630xex31d2.htm (EX-31.2) — 14KB
• prpo-20250630xex32d1.htm (EX-32.1) — 6KB
• prpo-20250630xex32d2.htm (EX-32.2) — 6KB
• 0001558370-25-011390.txt ( ) — 8519KB
• prpo-20250630.xsd (EX-101.SCH) — 56KB
• prpo-20250630_cal.xml (EX-101.CAL) — 75KB
• prpo-20250630_def.xml (EX-101.DEF) — 223KB
• prpo-20250630_lab.xml (EX-101.LAB) — 461KB
• prpo-20250630_pre.xml (EX-101.PRE) — 374KB
• prpo-20250630x10q_htm.xml (XML) — 1756KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 33 PART II. Other Information 34 Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2 . Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3 . Defaults Upon Senior Securities 35 Item 4 . Mine Safety Disclosures 35 Item 5 . Other Information 35 Item 6. Exhibits 36

Signatures

Signatures 37 2 Table of Contents PART 1. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements PRECIPIO, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except share data) (unaudited) June 30, 2025 December 31, 2024 ASSETS CURRENT ASSETS: Cash $ 1,130 $ 1,389 Accounts receivable (net of allowance for credit losses of $ 932 and $ 995 , respectively) 1,488 799 Inventories 1,059 724 Other current assets 376 539 Total current assets 4,053 3,451 PROPERTY AND EQUIPMENT, NET 756 719 OTHER ASSETS: Finance lease right-of-use assets, net 797 517 Operating lease right-of-use assets, net 1,756 395 Intangibles, net 11,394 11,869 Other assets 60 45 Total assets $ 18,816 $ 16,996 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current maturities of long-term debt, less debt issuance costs $ 29 $ 297 Current maturities of finance lease liabilities 171 124 Current maturities of operating lease liabilities 236 201 Accounts payable 1,164 618 Accrued expenses 2,475 2,799 Deferred revenue 278 232 Total current liabilities 4,353 4,271 LONG TERM LIABILITIES: Long-term debt, less current maturities and debt issuance costs 62 77 Finance lease liabilities, less current maturities 570 348 Operating lease liabilities, less current maturities 1,543 206 Total liabilities 6,528 4,902 COMMITMENTS AND CONTINGENCIES (Note 5) STOCKHOLDERS' EQUITY: Preferred stock - $ 0.01 par value, 15,000,000 shares authorized at June 30, 2025 and December 31, 2024, 47 shares issued and outstanding at June 30, 2025 and December 31, 2024, liquidation preference of $ 65 at June 30, 2025 — — Common stock, $ 0.01 par value, 150,000,000 shares authorized at June 30, 2025 and December 31, 2024, 1,516,296 and 1,493,639 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 15 15 Additional paid-in capital 115,523 114,519 Accumulated deficit

View Full Filing

View this 10-Q filing on SEC EDGAR